- Details
- In this UroToday GU Oncology Journal Club, Christopher Wallis and Zachary Klaassen highlight a Journal of Clinical Oncology publication on a phase two open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma, progressing after platinum-based chemotherapy and checkpoint inhibitors. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With M...
|
- Details
- In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss a publication entitled Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: a Post Hoc Analyses of the ARCHES trial . The present study relies upon secondary analysis of the ARCHES trial, a multinational randomized controlled trial th...
|
- Details
- In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss the Clinical Cancer Research publication on the results from the CONDOR Phase 3, multicenter study. In particular, conventional imaging performs poorly when PSA levels are low, less than 2 ng/mL, and the use of novel PET radiotracers may address this issue and provide more sensitive imaging. CONDOR was a prospective stu...
|
- Details
- In this Journal Club, Christopher Wallis and Zachary Klaassen highlight a subset analysis from the ENZAMET trial looking at the impact of enzalutamide on survival outcomes in men whose cancer comes back years later after diagnosis. The ENZAMET trial randomly assigned 1,125 metastatic hormone-sensitive prostate cancer (mHSPC) patients from March 31, 2014, to March 24, 2017: 562 in the non-steroidal...
|
- Details
- The BRAVO-Feasibility Study was designed to understand whether a randomized trial comparing intravesical maintenance Bacillus Calmette-Guerin (BCG) and radical cystectomy (RC) for the treatment of high-grade non-muscle invasive bladder cancer (NMIBC) is possible. This trial was a two-arm, prospective multicenter randomized study to determine the feasibility in BCG-naive patients, in which patients...
|
- Details
- In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen highlight a systematic review and meta-analysis examining the effectiveness and toxicities of lutetium-177-labeled prostate-specific membrane antigen-targeted radioligand therapy in metastatic castration-resistant prostate cancer, an article published in European Urology. Drs. Wallis and Klaassen detail the analysis, objective,...
|
- Details
- In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss The Journal of Urology publication on the Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate-Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY). Prostate cancer staging is critical in multiple steps in the disease continuum, from the initial diagnosis to the...
|
- Details
- In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen provide insights into the Cancer Treatment Reviews publication Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice. In the context of metastatic urothelial carcinoma, avelumab has previously been assessed in a large phase 1b study, using a...
|
- Details
- Christopher Wallis and Zachary Klaassen provide insights into the European Urology publication titled " Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis " in this UroToday Journal Club. The question that the authors sought to assess is if data could be derived assessing whether...
|
- Details
- In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen provide insights into the JAMA Oncology publication titled Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. The management of patients with localized and recurrent prostate cancer is driven predominantly at this point by cli...
|
